Overview

Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess the implications of switching from insulin glargine (IGlar) to insulin degludec (IDeg) in subjects with type 2 diabetes mellitus.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc
Insulin, Long-Acting